Hormone therapy for prostate cancer and the risk of stroke: A 5-year follow-up study

BJU International

Volumn 109, Issue 7, 2012, Pages 1001-1005

  Chung, Shiu Dong ^a,b   Chen, Yi Kuang ^b,c   Wu, Fang Jen ^b,c   Lin, Herng Ching ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Taipei County Hospital   (Taiwan)

Author keywords

androgen deprivation therapy; epidemiology; prostate cancer

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CHINESE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SURVIVAL RATE; TAIWAN;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; STROKE; TAIWAN;

EID: 84858025902     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10459.x     Document Type: Review

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 (Pubitemid 40372904)
2. Levine GN, D'Amico AV, Berger P, et al,. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-40
3. Suzuki H, Kamiya N, Imamoto T, et al,. Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 2008; 13: 401-10
4. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64 (Pubitemid 40096612)
5. Smith MR,. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-54 (Pubitemid 46684481)
6. Bolla M, de Reijke TM, Van Tienhoven G, et al,. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27
7. Braga-Basaria M, Dobs AS, Muller DC, et al,. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83 (Pubitemid 46630747)
8. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV,. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302: 866-73
9. Akishita M, Hashimoto M, Ohike Y, et al,. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis 2010; 210: 232-6
10. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46
11. Van Hemelrijck M, Garmo H, Holmberg L, et al,. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 2010; 28: 3448-56
12. Yeap BB, Hyde Z, Almeida OP, et al,. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353-9
13. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45 (Pubitemid 33741879)
14. Sasagawa I, Nakada T,. Epidemiology of prostatic cancer in East Asia. Arch Androl 2001; 47: 195-201 (Pubitemid 32980665)
15. Heald CL, Ritchie MR, Bolton-Smith C, Morton MS, Alexander FE,. Phyto-oestrogens and risk of prostate cancer in Scottish men. Br J Nutr 2007; 98: 388-96 (Pubitemid 47091381)
16. Kokubo Y, Iso H, Ishihara J, et al,. Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infartions in Japenese populations. Circulation 2007; 116: 2553-62 (Pubitemid 350179220)
17. Bain CAL, Lees KR, Lumsden MA, Walters MR,. Effect of a gonadotropin releasing hormone analog on cerebral hemodynamics in premenopausal women. Climacteric 2005; 8: 193-7 (Pubitemid 40862996)
18. Nelson CJ, Lee JS, Gamboa MC, Roth AJ,. Cognitive effects of hormone therapy in men with prostate cancer: a Review. Cancer 2008; 113: 1097-106
19. Gronberg H,. Prostate cancer epidemiology. Lancet 2003; 361: 859-64 (Pubitemid 36331852)
20. Uchida M, Palmateer JM, Herson PS, Devries AC, Cheng J, Hurn PD,. Dose-dependent effects of androgens on outcome after focal cerebral ischemia in adult male mice. J Cereb Blood Flow Metab 2009; 29: 1454-62
21. Abbott RD, Launer LJ, Rodriguez BL, et al,. Serum estradiol and risk of stroke in elderly men. Neurology 2007; 68: 563-8
22. Wong WY, Chen SC, Chueh SC, Chen J,. The trend of managing prostate cancer in Taiwan. Int J Urol 2004; 11: 510-4 (Pubitemid 39070738)
23. Food and Drug Administration, Department of Health, Taiwan. Available at:. Accessed 10 December, 2010